BeiGene, Ltd.'s near-term ambitions to bring a second drug to the US market after its BTK inhibitor Brukinsa (zanubrutinib) are linked to the PD-1 inhibitor tislelizumab, which is partnered with Novartis AG and is currently pending at the US Food and Drug Administration for advanced or metastatic esophageal cancer.
Novartis recently announced its decision not to file tislelizumab as a monotherapy in non-small cell lung cancer, however, citing the...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)



